top of page


  1. Schlag A, Baldwin D, Barnes M, et al.  Medical cannabis in the UK: from principle to practice. J Psychopharmacol 2020; 34:931-937

  2. Nutt DJ, Phillips LD, Barnes MP, et al. A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. Cannabis and Cannabinoid Research March 2021.

  3. Barnes MP. Medical cannabis – time for change.  ACNR 2018; 17(5): 16-17Barnes MP.  The case for medical cannabis – an essay by M P Barnes.  BMJ 2018;362:k3230    doi: 10.1136/bmj.k3230 (Published 25 July 2018)

  4. Alderman N, Pink AE, Williams C, da Silva Ramos S, Oddy M, Knight C, Jenkins K, Barnes MP, Hayward C. Optimizing measurement for neurobehavioural rehabilitation services: A multisite comparison study and response to UKROC. Neuropsychol Rehabil 2019 Mar 7:1-30. doi: 10.1080/09602011.2019.1582432.

  5. Barnes M, Kocer S, Murie-Fernandez M, et al.  An international survey of patients living with spasticity. Disability and Rehabilitation 2016, published on line 6 July 2016 (DOI:10.1080/09638288.2016.1198432) 

  6. Turner-Stokes L, Ashford S, Esquenazi A, et al.  Applying a comprehensive patient-centred approach to adult spastic paresis: a consensus framework. Accepted for publication

  7. The need for long term rehabilitation after traumatic brain injury.  Journal of Personal Injury Law 2012; Issue 2: 106-111

  8. Pituitary problems after brain injury.  APIL PI Focus October 2011; Vol 21: Issue 8

  9. Shaw LC, Price CIM, van Wijck FMJ  et al and on behalf of the BoTULS investigators.  Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation, and pain. Stroke 2011 42(5): 1371-9

  10. Shackley P, Shaw L, Price C et al.  Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) trial.  Toxins 2012; 4(12): 1415-1426

  11. Thomas R, Barnes M. Life Expectancy for people with disabilities. Neurorehabilitation 2010; 27(2): 201-209

  12. Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert-Batar A, Minnasch P.  Efficacy and safety of NT 201 for upper limb spasticity of various etiologies — a randomised parallel-group study.  Acta Neurol Scand 2010; 122(4): 295-302. PMID: 20456248

  13. Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L, on behalf of the BoTULS investigators.  BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.  Health Technology Assessment 2010; 14(26): 1 -113

  14. Anwar K, Barnes MP.  A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis.  Neurorehabilitation 2009; 24(4): 333-340

  15. Rodgers H, Shaw L, Price C, et al.  Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Trials 2008; 9: 59

  16. Carroll A, Barnes M, Comiskey C.  A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder.  Clin Rehab 2008; 22: 513-519

  17. Farbu E, Gilhus NE, Barnes MP, et al.  EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur J Neurol 2006; 13: 795-801

  18. Barnes M, Wittchen H, Troostwijk A, Gauci D.  Improving life for people living with brain disease: psychosocial aspects.  In: Consensus document on European brain research. JNNP 2006; 77 (Suppl I): i35-i36

  19. Barnes MP.  Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.  Expert Opinion on Pharmacotherapy 2006; 7(5): 607-15

  20. Albanese A, Barnes MP, Bhatia KP, et al.  A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes.  Report by an EFNS/MDS-ES Task Force.  Eur J Neurol 2006; 13: 433-44

  21. Pandyan AD, van Wijck FMJ, Stark S, Vuadens P, Johnson GR, Barnes MP.  The construct validity of a spasticity measurement device for clinical practice: an alternative to the Ashworth scales.  Disabil Rehabil 2006; 28: 579-85

  22. Pandyan AD, Cousins E, van Wijck F, Barnes MP, Johnson GR.  Spasticity research: some common catches.  Arch Phys Med Rehabil 2005; 86(4): 845-51

  23. Barnes MP.  The management of spasticity.  Farmakoterapia W Psychiatrii I Neurologii 2005; 3: 241-248

  24. Barnes M , Best D, Kidd L, Roberts B, Stark S, Weeks P, Whitaker J.  The use of botulinum toxin type B in the treatment of patients who have become unresponsive to botulinum toxin type A – initial experiences. Eur J Neurol  2005; 12: 947-955

  25. Anwar K, Barnes MP. Botulinum toxin injections for spasticity.  Operative Techniques in Neurosurgery – Neurosurgical Management of Disabling Spasticity 2005; 7: 128-135

  26. Pandyan AD, Gregoric M, Barnes MP, Wood D, van Wijck F, Burridge J, Hermens H, Johnson GR.  Spasticity: clinical perceptions, neurological realities and meaningful measurement.  Disabil Rehabil 2005; 27 (1/2): 2-6

  27. Barnes MP.  Community neurological rehabilitation.  Saudi Journal of Disability and Rehabilitation 2004; 10 (2): 166-176

  28. Salazar-Torres J de J, Pandyan AD, Price CI, Davidson, RI, Barnes MP, Johnson GR.  Does spasticity result from hyperactive stretch reflexes? Preliminary findings from a stretch reflex characterization study. Disabil Rehabil 2004; 26(12): 756-60

  29. Hemmett L, Holmes J, Barnes M, Russell N.  What drives quality of life in multiple sclerosis?  

  30. Barnes MP.  Life expectancy for people with disabilities.  J.P.I. Law 2004; 2: 131-155

  31. Brainin M, Barnes M, Gilhus NE, Selmaj K, Waldemar G, Hughes R.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004.  Eur J Neurol 2004 11: 577-581

  32. Barnes M, Jones C.  Cannabis for MS: where next?   Progress in Neurology & Psychiatry 2004; 8(1): 7

  33. Barnes MP.  Community rehabilitation after stroke.  Crit Rev Phys & Rehab Med 2003; 15 (3&4): 223-234

  34. Carroll A, McDonnell G, Barnes M.  A review of the management of Guillain-Barré syndrome in a regional neurological rehabilitation unit.  Int J Rehab Res 2003; 26(4): 297-202

  35. Barnes MP.  Principles of neurological rehabilitation.  J Neurol Neurosurg Psychiatry 2003; 74 (Suppl IV): iv3-iv7

  36. Barnes MP.  Botulinum toxin – mechanisms of action and clinical use in spasticity.  J Rehabil Med 2003; Suppl 41: 56-59

  37. Pandyan AD, Price, CI, Barnes MP, Johnson GR.  A biomechanical investigation into the validity of the modified Ashworth Scale as a measure of elbow spasticity.  Clin Rehabil 2003; 17(3): 290-293

  38. Barnes MP, Kent RM, Semlyen JK, McMullen KM.  Spasticity in multiple sclerosis.  Neurorehabilitation & Neural Repair 2003; 17(1): 66-70

  39. Barnes MP.  The modern management of adult spasticity: an evidence based approach.  Eur J Neurol 2002; 9 (Suppl 1): 2 & 53-61

  40. Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP.  Are we underestimating the clinical efficacy of botulinum toxin (type A)?  Quantifying changes in spasticity, strength and upper limb function after injections of Botox® to the elbow flexors in a unilateral stroke population. Clin Rehabil 2002; 16(6): 654-660

  41. Carroll AM, Barnes MP.  Life expectancy determination.  Physical Medicine & Rehabilitation Clinics of North America 2002; 13: 309-332

  42. Pandyan AD, Price CIM, Rodgers H, Barnes MP, Johnson GR.  A clinical tool to measure resistance to passive movement: a biomechanical alternative to the clinical grading of spasticity.  Clin Rehab 2001; 15(4): 448-449

  43. Makepeace RW, Barnes MP, Semlyen JK, Stevenson J.  The establishment of a community multiple sclerosis team.  Int J Rehab Res 2001; 24(2): 137-141

  44. Barnes MP.  Community rehabilitation after stroke.  Saudi Journal of Disability and Rehabilitation 2001; 7(2): 91-96

  45. Barnes MP.  CBR – lessons for the North.  Asia Pacific Disability & Rehabilitation Journal 2001; 12(2): 83-87

  46. Hughes RAC, Barnes MP, Baron JC, Brainin M.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces.  Eur J Neurol 2001; 8: 549-550

  47. Pandyan AD, Price, CI, Rodgers H, Barnes MP, Johnson GR.  Biomechanical examination of a commonly used measure of spasticity.  Clin Biomech 2001; 16(10): 859-865

  48. Barnes MP.  Spasticity: a rehabilitation challenge in the elderly.  Gerontology 2001; 47(6): 295-299

  49. Barnes MP, Radermacher H.  Neurological rehabilitation in the community.  J Rehabil Med 2001; 33(6): 244-248

  50. van Wijck FM, Pandyan AD, Johnson GR, Barnes MP.  Assessing motor deficits in neurological rehabilitation: patterns of instrument usage.  Neurorehabil Neural Repair 2001; 15(1): 23-30

  51. Barnes MP.  Practical aspects of using botulinum toxin type B.  Eur J Neurol 2001; 8(4): 19-21

  52. Whitaker J, Butler AG, Semlyen JK, Barnes MP.  Botulinum toxin for people with dystonia treated by an outreach nurse practitioner – a comparative study between a home and a clinic treatment service.  Arch Phys Med Rehabil 2001; 82(4): 480-484 

  53. Barnes MP, Gilhus NE, Wender M.  EFNS Task force on minimum standards for health care of people with multiple sclerosis: June 1999.  Eur J Neurol 2001; 8(3): 215-220

  54. Barnes MP.  Medical management of spasticity in stroke.  Age Ageing 2001; 30(S1): 13-16

  55. Jones C, Barnes M, Percy J, Johnson J.  Multiple sclerosis.  Primary Health Care 2000; 10(4): 29-34

  56. Barnes MP, Bassett L, Broughton S et al.  Guidelines for the management of spasticity in primary care.  Progress in Neurology & Psychiatry 2000; 4(2): 23-27

  57. Barnes MP.  Botulinum toxin in the treatment of cerebral palsy.  J Neurol Neurosurg & Psychiatry 2000; 68(6): 801

  58. Kent RM, Chandler BJ, Barnes MP.  An epidemiological survey of the health needs of disabled people in a rural community.  Clin Rehabil 2000; 14(5): 481-490

  59. Hyman N, Barnes M, Bhakta B et al.  Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind placebo-controlled, dose ranging study.  J Neurol Neurosurg Psychiatry 2000; 68: 707-712

  60. Davis EC, Barnes MP.  Botulinum toxin and spasticity.  (Editorial).  J Neuro Neurosurg & Psychiatry 2000; 69(2): 143-147

  61. Barnes MP.  Zanaflex (tizanidine hydrochloride) in spasticity management.  Br J Ther Rehabil 2000; 7(4): 192-196

  62. Barnes MP.  Rehabilitation after traumatic brain injury.  British Medical Bulletin 1999; 55(4): 927-943

  63. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H.  A review of the properties and limitations of the Ashworth & modified Ashworth Scales as measures of spasticity.  Clin Rehabil 1999; 13(5): 373-383 

  64. Barnes MP.  Neurologic rehabilitation in the United Kingdom.  J Neuro Rehab 1998; 12: 91

  65. Semlyen JK, Summers SJ, Barnes MP. Aspects of caregiver distress after severe head injury. J Neuro Rehab 1998; 12: 53-60

  66. Butler AG, Duffey PO, Hawthorne MR, Barnes MP.  The socio-economic implications of dystonia.  Adv Neurol 1998; 78: 349-358

  67. Duffey PO, Butler AG, Hawthorne MR, Barnes MP.  The epidemiology of primary dystonias in the North of England.  Adv Neurol 1998; 78: 121-125

  68. Semlyen JK, Summers SJ, Barnes MP.  Traumatic brain injury: efficacy of multidisciplinary rehabilitation.  Arch Phys Med Rehabil 1998; 79(6): 678-683

  69. Semlyen JK, Barnes MP.  The further validation and precision of the NIAF-R.  Br Inj 1998; 12(2): 155-164

  70. Barnes MP.  Management of spasticity.  Age Ageing 1998; 27: 239-245

  71. Barnes MP.  Treating and nursing patients with multiple sclerosis.  Nursing Standard 1997; 11(23): 42-44

  72. Semlyen JK, Summers SJ, Barnes MP.  The predictive validity of the Newcastle Independence Assessment Form Research (NIAF-R):  Further development of an alternative measure.  J Neurol Rehab 1997; 11: 213-218

  73. Barnes MP.  Trauma and rehabilitation.  Curr Opin Neurol 1997; 10: 477-78

  74. Barnes MP, Gerstenbrand, F, Gilhus NE, et al.  Minimum standards in neurological rehabilitation, June 1997.  Eur J Neurol 1997; 4: 325-331

  75. Barnes MP.  Driving for disabled people.  Crit Rev Phys & Rehab Med 1997; 9: 75- 92

  76. Young RR, Emre M, Nance PW, Schapiro R, Barnes MP.  Current issues in spasticity management.  The Neurologist 1997; 3(4): 261-275

  77. Duffey P, Butler AG, Barnes MP.  The epidemiology of the primary dystonias in the North of England.  Mov Disord 1997; 12(3): 18

  78. Barnes MP.  Management of spasticity.  Eur Med Phys 1997; 32: 1-7

  79. Hyman N, Barnes M, Bhakta B et al.  Botulinum toxin (Dysport) treatment of upper leg adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, placebo-controlled, dose ranging study.  Eur J Neurol 1997; 4(Suppl 1): 82

  80. Barnes MP, Skeil DA.  Outpatients in neurological rehabilitation - How do we deliver the service? Int J Rehab Res 1996; 19(1): 39-45

  81. Semlyen JK, Hurrell E, Carter S, Barnes MP.  The Newcastle Independence Assessment Form (Research): development of an alternative functional measure.  J Neuro Rehab 1996; 10(4): 251-257

  82. Barnes MP.  Riabilitazione e terapia occupazionale in Gran Bretagna.  Europa Medicophysica 1995; 31(Suppl 1): 21-23

  83. Barnes MP, Hoyle EA.  Driving assessment - a case of need.  Clin Rehabil 1995; 9: 115-120

  84. United Kingdom Tizanidine Trial Group.   A double-blind placebo-controlled trial of Tizanidine in the treatment of spasticity caused by multiple sclerosis.  Neurology 1994; 44(Suppl 9): S70-S78

  85. Barnes MP.  Switching devices and independence of disabled people.  BMJ 1994; 309(6963): 1181-1182

  86. Jordan N, Barnes MP.  Botulinum toxin therapy: clinical and financial considerations.  Clin Rehabil 1994; 8: 358-361

  87. Barnes MP.   Environmental control systems - an audit and review.  Clin Rehabil 1994; 8: 362-366

  88. Skeil DA, Barnes MP.  The local treatment of spasticity.  Clin Rehabil 1994; 8: 240-246

  89. Williams A, Barnes MP, Brookes GB et al.   Consensus statement for the management of focal dystonia.  Br J Hosp Med 1993; 50: 655-659

  90. Castree BJ, Barnes MP.  Adults with physical disability in institutional care: Do they have a  choice?  Int J Rehab Res 1993; 16(2): 143-147        

  91. Pentland B, Barnes MP, Findlay LJ, et al.   Parkinson's disease: The spectrum of disabilities.  J Neurol Neurosurg Psychiatry 1992; 55(Suppl): 32-35

  92. Barnes MP.  Young People with Physical Disability   Can more be done?  Society of Public Health Medicine 1991. Edinburgh

  93. Barnes MP.  Outcome of head injury.  Curr Opin Neurol Neurosurg 1991; 4: 12 16

  94. Barnes MP.  Services for people with physical disabilities in the north of England.  Clin Rehabil 1991; 5: 79 81

  95. Pentland B, Barnes MP.  Staffing provision for early head injury rehabilitation.  Clin Rehabil 1988; 2: 309 313

  96. Walsh KJ, Barnes MP, McLellan DL.  A rehabilitation ward in a district general hospital:  a description of the first three years’ experience.  BMJ 1988; 297(6658): 1252 1256

  97. Barnes MP, Bates D, Cartlidge NEF et al.  Hyperbaric oxygen and multiple sclerosis.   Final results of a placebo controlled, double blind trial.  J Neurol Neurosurg Psychiatry 1987; 50(11): 1402 1406

  98. Barnes MP.  Management of the elderly patient  with cervical spondylotic myelopathy.  Geriatric Med 1986; 5: 53 60

  99. Barnes MP, Saunders M, Walls TJ et al.   The syndrome of Karl Ludwig Kahlbaum.   J  Neurol Neurosurg Psychiatry 1986; 49(9): 991 996

  100. Barnes MP, Bates D, Cartlidge NEF et al.  Hyperbaric oxygen and multiple sclerosis.   Short-term results of a placebo controlled, double blind trial.  Lancet 1985; 1(8424): 297 300

  101. Barnes MP, Bateman DE, Cleland PG et al.  Intravenous methylprednisolone for multiple sclerosis in relapse.  J Neurol Neurosurg Psychiatry 1985; 48(2): 157 159

  102. Barnes MP, Newman PK.  Delayed  encephalopathy following cardiac arrest.  Postgrad Med J 1985; 61(713): 253 254

  103. Barnes MP, Saunders M.  The effect of cervical mobility on the natural history of cervical  spondylotic myelopathy.  J Neurol Neurosurg Psychiatry 1984; 47(1): 17 20

  104. Whicher JT, Barnes MP, Brown A et al.  Complement activation and complement control proteins in acute pancreatitis.  Gut 1982; 23(11): 944 950

  105. Barnes MP, Hunt BJ, Williams IR.  The role of vertebral  angiography in the investigation of third nerve palsy.  J Neurol Neurosurg Psychiatry 1981; 44(12): 1153 1155

  106. Barnes MP.   Influence of laboratory reports on prescribing of antimicrobials for urinary tract infection.  J Clin Pathol 1980; 33(5): 481 483

bottom of page